Photobiomodulation Therapy to Mitigate Radiation Fibrosis Syndrome

Tam, Moses; Arany, Praveen; Robijns, Jolien; Vasconcelos, Rodrigo Nogueira de; Corby, Patricia; Hu, Kenneth

doi:10.1089/photob.2019.4766

Cited by 4 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,[30][31][32][33][34] Besides, PBM has been reported to alleviate radiation fibrosis syndrome caused by cancer radiation therapy. 35 Consistent with these reports, our study confirmed that PBM improved endometrial fibrosis in IUA rats in vivo and TGF-β1induced ESCs fibrosis in vitro. In addition, re-epithelialization of the endometrium is essential for its recovery following pathological injury and scar-free repair after a physiological menstrual breakdown in humans.…”

Section: Discussionsupporting

confidence: 91%

“…According to previous reports, red and infrared PBM could reduce tissue fibrosis in the lungs, kidneys, skin, pulp, muscles, and tendons 9,30–34 . Besides, PBM has been reported to alleviate radiation fibrosis syndrome caused by cancer radiation therapy 35 . Consistent with these reports, our study confirmed that PBM improved endometrial fibrosis in IUA rats in vivo and TGF‐β1‐induced ESCs fibrosis in vitro.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Photobiomodulation therapy at 632 nm wavelength ameliorates intrauterine adhesion via activation of cAMP/PKA/CREB pathway

Zheng

Wang

et al. 2023

Photochem & Photobiology

View full text Add to dashboard Cite

Intrauterine adhesion (IUA), a major cause of uterine infertility, is pathologically characterized by endometrial fibrosis. Current treatments for IUA have poor efficacy with high recurrence rate, and restoring uterine functions is difficult. We aimed to determine the therapeutic efficacy of photobiomodulation (PBM) therapy on IUA and elucidate its underlying mechanisms. A rat IUA model was established via mechanical injury, and PBM was applied intrauterinely. The uterine structure and function were evaluated using ultrasonography, histology, and fertility tests. PBM therapy induced a thicker, more intact, and less fibrotic endometrium. PBM also partly recovered endometrial receptivity and fertility in IUA rats. A cellular fibrosis model was then established with human endometrial stromal cells (ESCs) cultured in the presence of TGF‐β1. PBM alleviated TGF‐β1‐induced fibrosis and triggered cAMP/PKA/CREB signaling in ESCs. Pretreatment with the inhibitors targeting this pathway weakened PBM's protective efficacy in the IUA rats and ESCs. Therefore, we conclude that PBM improved endometrial fibrosis and fertility via activating cAMP/PKA/CREB signaling in IUA uterus. This study sheds more lights on the efficacy of PBM as a potential treatment for IUA.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Photobiomodulation therapy at 632 nm wavelength ameliorates intrauterine adhesion via activation of cAMP/PKA/CREB pathway

Zheng

Wang

et al. 2023

Photochem & Photobiology

View full text Add to dashboard Cite

show abstract

“…The available evidence demonstrates that PBM can regulate the main targets of the fibrosis pathway ranging from the reduction of the fibroblast proliferation and migration speed, inhibition of the production of TGF-β and the related pathway, to the downregulation of the production and deposition of collagen ( 247 ). There are currently no published clinical studies using PBM to address RIF ( 250 ). Currently, investigators at New York University are evaluating the feasibility, safety, and tolerability of providing PBM for the treatment of RIF in HNC patients treated with RT.…”

Section: Resultsmentioning

confidence: 99%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

Self Cite

View full text Add to dashboard Cite

DisclaimerThis article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols.ObjectiveThis position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).BackgroundThere is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care.MethodsA literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed.ResultsThere is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors.ConclusionsThere is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.

show abstract